Klaria Pharma (KLAR) Q4 2024 earnings summary

Executive summary

• Achieved two major milestones: market approval for Sumatriptan Alginate Film in Germany, Italy, and Spain, and a license agreement with CNX Therapeutics for European and UK commercialization, with initial launch planned for H2 2025.

• Focused on transitioning from a development company to a profitable pharmaceutical company, with additional licensing agreements targeted outside Europe in the next twelve months.

• Continued progress in three other development projects, with updates expected in 2025.

Financial highlights

• Net sales for 2024 were SEK 2.2 million, down from SEK 8.5 million year-over-year.

• R&D expenses for the year totaled SEK 22.1 million, compared to SEK 24.9 million in 2023.

• Profit after tax was SEK -47.8 million, a deeper loss than SEK -35.8 million in 2023.

• Cash and cash equivalents at year-end were SEK 0.6 million, down from SEK 1.2 million.

• Equity at year-end was SEK 3.3 million, a significant decrease from SEK 41.1 million.

Outlook and guidance

• Initial launch of Sumatriptan Alginate Film in Germany, Spain, and Italy expected in H2 2025, with further European expansion in 2026.

• Targeting at least one additional licensing agreement outside Europe within the next twelve months.

• Updates on three other development projects anticipated in 2025.